We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About Antabio Stock

Invest in or calculate the value of your shares in Antabio or other pre-IPO companies through EquityZen's platform.

Get Started

Antabio Stock

Antabio is a private biopharmaceutical company developing antibacterial resistance-breakers in areas of highest medical need.

About Antabio Stock

Founded

2009

Industries

Software, Data and Analytics, Artificial Intelligence

Antabio is a private biopharmaceutical company developing novel antibacterial resistance-breakers to treat drug-resistant infections in areas of highest unmet medical need. It develops stand-alone inhibitors of bacterial metalloenzymes that can be combined with various antibiotics to restore their activity against the most critical pathogens. The company's novel inhibitor of bacterial Metallo ß-lactamases (“MBLs”) which will be combined with a carbapenem to fill an important gap in the treatment of drug-resistant infections. They develop a novel, safe and efficacious inhibitor of bacterial Metallo ß-lactamases to be combined with a carbapenem for the treatment of drug-resistant nosocomial infections. Antabio received a Wellcome Trust Seeding Drug Discovery Award. The company was founded in 2009 and is headquartered in Labege, France.

Antabio Press Mentions

Stay in the know about the latest news on Antabio

Indane derivatives for use in the treatment of bacterial infection

patents • Apr 15, 2024

Combination therapy

patents • Apr 15, 2024

Chemical compounds

patents • Apr 15, 2024

ANTABIO Raises €25 Million in Series B Financing

pharmaceuticalmanufacturer • Feb 10, 2024

Higher levels of Pseudomonas aeruginosa LasB elastase ...

nature • Jan 25, 2024

Antabio Management

Leadership team at Antabio

Chief Scientific Officer

Martin Everett

Non Executive Board member

Helmuth van Es

Locked Features

Join now and verify your accreditation status to gain access to:

  • Antabio current valuation
  • Antabio stock price
  • Available deals in Antabio and all other companies
  • Deal offering documents
  • EquityZen's proprietary data and insights, including
    • Cap tables, which include funding history by Share Class and Liquidity Preferences
    • Company Highlights
    • Business Model
    • Risk Factors
Join Now

How to invest in Antabio stock?

Accredited investors can buy pre-IPO stock in companies like Antabio through EquityZen funds. These investments are made available by existing Antabio shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell Antabio stock?

Shareholders can sell their Antabio stock through EquityZen's private company marketplace. EquityZen's network includes over 310K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 42K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."